DCP (RaDiCo Cohort) (RaDiCo-DCP)

Recruiting

• Conditions: Primary Ciliary Dyskinesia

• Registration Number: NCT05951478
• Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Brief Summary

Primary Ciliary Dyskinesias (PCD) are rare, autosomal recessive respiratory diseases, due to a defect in mucociliary clearance linked to abnormalities in the structure and/or function of the cilia. The variety of ciliary abnormalities identified reflects the genetic heterogeneity of PCDs. The thirty or so genes currently implicated explain the pathology in about half of the patients. PCDs are characterized by recurrent infections of the upper (rhinosinusitis) and lower (bronchitis) airways, beginning in early childhood and progressing respectively to nasal polyposis and bronchial dilatation. In half of the cases, there is a lateralization defect of the organs (situs inversus) corresponding to Kartagener's syndrome. There is more frequent infertility in men (immobility of spermatozoa) than in women (miscarriages and tubal pregnancies). About a third of patients progress to respiratory failure. The identification of predictive factors of severity, specific to PCDs, would improve patient care. It is also important to assess the quality of life of patients with PCD, particularly at the ENT level.

Data from prevalent patients are currently integrated into three separate and complementary databases: the "e-RespiRare" database, the "DCP Cils" database and the "DCP genes" database. The first step is therefore to constitute the RaDiCo-DCP database which will include data from prevalent and incident patients whose diagnosis of PCD is certain.

The cohort aims to improve the routine care of PCD patients, in particular by highlighting predictive factors of severity, allowing early and personalized care, to assess the social impact (quality of life) and medical conditions of ENT impairment, as well as adult infertility, to finely characterize the ciliary phenotype. The study also aims to search for new DCP genes and to allow genotype/phenotype correlation studies.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-05-01
• Study First Submitted: 2022-05-06
• Study First Submitted QC: 2023-07-18
• Study First Posted: 2023-07-19
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-04
• Last Update Posted: 2025-02-07
• Primary Completion: 2027-05-01
• Study Completion: 2027-05-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Patient fulfilling at least one of the following criteria for PCD confirmed diagnosis: Kartagener's syndrome and/or specific anomaly of the ciliary ultrastructure and/or an unambiguous mutation in a PCD gene
• Having at least one annual follow-up visit

Non-inclusion Criteria:

• Patients with an unconfirmed diagnosis of PCD
• Patients with an evolving concomitant pathology that may interfere with the assessment of PCD-related manifestations

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison and description for severe and non-severe patients of the phenotypic characteristics of the disease in adult and pediatric patients.	Through study completion, an average of 5 years

Secondary Outcome Measures

Name	Time	Method
Impact of disease on quality of life will be evaluated through scores of quality of life questionnaire Best Cilia 18+ years old	Through study completion, an average of 5 years
Impact of disease on quality of life will be evaluated through scores of quality of life questionnaire Sino-nasal outcome test-22	Through study completion, an average of 5 years
Impact of disease on quality of life will be evaluated through scores of quality of life questionnaires Best Cilia 6-12 years old	Through study completion, an average of 5 years
Validation of the involvement of new DCP genes	Through study completion, an average of 5 years	Validation of the involvement of new DCP genes highlighted in the context of medical care will be done by association study in well-defined subgroups of patients.
Impact of disease on quality of life will be evaluated through scores of quality of life questionnaire Best Cilia 13-17 years old	Through study completion, an average of 5 years

Trial Locations

Locations (28)

CHU de Caen; 🇫🇷 Caen, France

Hôpital Jean Minjoz; 🇫🇷 Besançon, France

Hôpital Pellegrin-Enfants; 🇫🇷 Bordeaux, France

Hôpital Henri Mondor; 🇫🇷 Créteil, France

Hôpital Clémenceau; 🇫🇷 Caen, France

Centre Hospitalier Intercommunal de Créteil; 🇫🇷 Créteil, France

Hôpital Bicêtre; 🇫🇷 Le Kremlin-Bicêtre, France

Hôpital Le Bocage; 🇫🇷 Dijon, France

Hôpital Jeanne de Flandre; 🇫🇷 Lille, France

Hôpital Nord; 🇫🇷 Marseille, France

Hôpital Femme-Mère-Enfant; 🇫🇷 Lyon, France

Hôpital de la Timone; 🇫🇷 Marseille, France

Hôpital Louis Pradel; 🇫🇷 Lyon, France

Hôpital Armand Trousseau; 🇫🇷 Paris, France

Hôpital Arnaud de Villeneuve; 🇫🇷 Montpellier, France

Hôpital Lenval; 🇫🇷 Nice, France

Hôpital Bichat; 🇫🇷 Paris, France

Hôpital Cochin; 🇫🇷 Paris, France

Hôpital Robert Debré; 🇫🇷 Paris, France

Hôpital Necker-Enfants Malades; 🇫🇷 Paris, France

American Memorial Hospital; 🇫🇷 Reims, France

Hôpital Charles Nicolle; 🇫🇷 Rouen, France

Hôpital Tenon; 🇫🇷 Paris, France

Hospices Civils; 🇫🇷 Strasbourg, France

Hôpital Hautepierre; 🇫🇷 Strasbourg, France

Hôpital de Clocheville; 🇫🇷 Tours, France

Hôpital des Enfants; 🇫🇷 Toulouse, France

Hôpital Larrey; 🇫🇷 Toulouse, France